...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS
【24h】

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS

机译：Elvitegravir / cobicistat / emtricitabine / tenofovir在治疗HIV / AIDS中的功效，安全性和患者可接受性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract: The fixed-dose combination (FDC) elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/c/FTC/TDF) is a once-daily, single-tablet regimen containing an integrase strand transfer inhibitor and a pharmacoenhancer (cobicistat) associated with two nucleos(t)ide reverse transcriptase inhibitors. It is approved as the preferred regimen and as the first-line combined antiretroviral therapy in treatment-na?ve patients with HIV infection. Two large trials, 102-Study and 103-Study, demonstrated that EVG/c/FTC/TDF was not inferior to efavirenz/FTC/TDF and ritonavir-boosted atazanavir in association with FTC/TDF, in terms of virological suppression and immunological reconstitution through week 144. Also, simplification arms containing EVG/c/FTC/TDF reached noninferiority in comparison with a nonnucleoside reverse transcriptase inhibitor, or a protease inhibitor, or a raltegravir-based regimen. Furthermore, EVG/c/FTC/TDF exhibited an excellent tolerability profile, with a safer lipid profile, and despite the indication of its use in subjects with an estimated creatinine clearance >70 mL/min, recent data demonstrated that EVG/c/FTC/TDF determined a reduction in estimated glomerular filtration rate (GFR) but not a reduction of actual GFR. Moreover, in a cohort of na?ve patients with pretreatment mild-to-moderate renal impairment, GFR decrease was noted as early at week 2, after which it generally stabilized and was nonprogressive through week 48. The FDC’s efficacy and good tolerability enable EVG/c/FTC/TDF to meet the patients’ needs, improving adherence and quality of life, which are among the most important factors affecting the therapeutic efficacy of an antiretroviral regimen. This paper describes the evidence making EVG/c/FTC/TDF a new therapeutic opportunity for different HIV-infected patients.
机译：摘要：固定剂量组合（FDC）Elvitegravir / cobicistat / emtricitabine / tenofovir（EVG / c / FTC / TDF）是每日一次的单片方案，包含整合酶链转移抑制剂和与以下药物相关的药物增强剂（cobicistat）：两种核苷酸（t）逆转录酶抑制剂。它已被批准为未接受过HIV感染的患者的首选方案和一线联合抗逆转录病毒疗法。两项大型研究（102项研究和103项研究）表明，就病毒学抑制和免疫重建而言，EVG / c / FTC / TDF并不逊色于依法韦仑/ FTC / TDF和利托那韦增强的阿扎那韦联合FTC / TDF直到第144周为止。与非核苷类逆转录酶抑制剂，蛋白酶抑制剂或基于raltegravir的治疗方案相比，含有EVG / c / FTC / TDF的简化治疗药物的疗效不差。此外，EVG / c / FTC / TDF表现出优异的耐受性，脂质分布更安全，尽管已表明其可用于估计肌酐清除率> 70 mL / min的受试者，但最近的数据表明，EVG / c / FTC / TDF确定了肾小球滤过率估计值（GFR）的降低，但实际GFR并未降低。此外，在一批接受过轻度至中度肾功能衰竭治疗的初次接受治疗的患者中，GFR下降最早在第2周出现，此后通常稳定并且在48周内没有进展。FDC的疗效和良好的耐受性使EVG / c / FTC / TDF满足患者的需求，改善依从性和生活质量，这是影响抗逆转录病毒疗法治疗效果的最重要因素之一。本文介绍了使EVG / c / FTC / TDF成为不同HIV感染患者新治疗机会的证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号